

DirectConnect

Inside Yale Cancer Center

June 12, 2020

Announcements

Smilow Cancer Hospital and our Care Centers have once again experienced a lot of change over the last two weeks, with the redesign and move of many of our ambulatory clinics back to our main hospital, and the reopening of Care Centers. Thank you to our Ambulatory Transformation team, and the leadership of Maureen Major Campos, RN, and Anne Chiang, MD, PhD, for their tremendous work transitioning many of our clinical teams, and to the Smilow Operations, Facilities, IT, and Epic teams for their amazing support. We cannot overstate our incredible appreciation to all of the members of our Clinical Programs impacted by the moves for their dedication to our patients, dependability, and flexibility.

As of Monday, June 8, the following programs have moved to new spaces in Smilow:

- Breast Cancer, Prostate and Urologic Cancers, Endocrine Cancers, and

from the desk of
Charles S. Fuchs, MD, MPH
Director, Yale Cancer Center
and Physician-in-Chief
Smilow Cancer Hospital



Yale
NewHaven
Health
Smilow Cancer
Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

Pain & Palliative Care are now located on NP 4.

- GI Surgery, Head and Neck Medical Oncology, Melanoma, Neurosurgery, GynOnc, Apheresis, and Ophthalmic Oncology are on NP 8.

In addition, our Fairfield Care Center reopened on May 29 and our Orange Care Center is scheduled to reopen on Monday, June 15.

Throughout all of our transitions, our patients have been resilient and dedicated to their treatment and care. Our commitment to keep our patients safe while in our facilities must be reiterated throughout our Cancer Enterprise, and safe practices must continue to be employed. To reiterate our commitment to our patients, we have sent a [letter](#) and invited participation in a [Patient and Family Forum: Partnering in Your Care](#). Additional opportunities are planned and we look forward to working with our entire team to help our patients through this transition.

Schwartz Rounds

Please join us on Tuesday, June 16 at Noon for a special [Schwartz Rounds](#) discussion on embracing diversity and inclusion at Yale Cancer Center and Smilow Cancer Hospital. We are fortunate to have Darin Latimore, MD, Deputy Dean for Diversity and Inclusion and Chief Diversity Officer for Yale School of Medicine, and Katherine Tucker, DNP, RN, APRN-BC, NE-BC, Clinical Program Director for

News Center



Reiki that - How Some Americans Use Alternative Medicine to Deal with Stress

[Read More >>](#)



Yale Cancer Researcher Discusses COVID-19 Study Underway on Antibodies

[Read More >>](#)



Yale Scientists Develop a New Experimental Method to Study Infection and Disease

[Read More >>](#)

the Heart and Vascular Center at Yale New Haven Hospital, serving as facilitators for this Schwartz Rounds. We hope you will join for this important event for our Yale Cancer Center and Smilow Cancer Hospital community.

Hematology-Medical Oncology Fellows Graduate

Congratulations to our nine 2020 graduates of the Yale Cancer Center Hematology-Medical Oncology Fellowship Program! We look forward to celebrating their accomplishments in an online graduation this evening, and again through a socially distanced event tomorrow morning. Each of them have presented the culmination of their research endeavors at Yale Cancer Center and Smilow Cancer Hospital through wonderful Research in Progress presentations over the last several days, and we appreciate their thoughtful work, and insightful contributions to our cancer research enterprise. We wish everyone well as they pursue the next steps in their careers, and are grateful for the contributions of the graduating class during their tenure at Yale Cancer Center.

Sabrina Browning, MD
Emily Collier, MD
Bryden Considine, DO
Suchin Khanna, MD
Ranjan Pathak, MBBS, MHS
Ashley Pariser, MD
Alexander Pine, MD, PhD
Rory Shallis, MD
Natalie Wallace, MD, MPH

Closer to Free Ride



Yale Cancer Center and Smilow Cancer Hospital Physicians Recognized as CT Magazine Best Doctors

[Read More >>](#)



Doctors Urge the Public to Seek Help for Cancer Screenings as Sharp Decline in Care Means Thousands of Untreated Cases

[Read More >>](#)



Yale Cancer Center Scientists Reveal How Mutations in Metabolism Can Drive Cancers

[Read More >>](#)

The 2020 Closer to Free Ride presented by Bank of America is redesigned into a virtual platform this year, requesting the Closer to Free community to choose a goal distance, train, fundraise, and ride to support patient care and cancer research at Smilow Cancer Hospital and Yale Cancer Center.

On September 12, we will still unite virtually to deliver the hope, love, and support together. Please join together in spreading the message of Closer to Free, and encouraging your colleagues, family, and friends to participate. [Closer to Free Ride](#).


Notables

Yale Cancer Center held their annual **Trainee Colloquium** last week, with presentations from 19 trainees from laboratories in all of our seven research programs. Abstracts were submitted from graduate students, MD students, residents, postdoctoral fellows/associates, and clinical fellows covering basic, translational, clinical, and population sciences. A special thanks to **Meina Wang, PhD**, Senior Research Project Manager in the Office of Translational Research, for her organization of the Colloquium, along with **Harriet Kluger, MD**, **David Stern, PhD**, **Jill Lacy, MD**, **James Yu, MD**, **MHS**, and **Anna Arnal Estape, PhD**. This year's award recipients are:

Basic Science:

Differential Pathway Engagement of KRAS Variants and Their Biological Implications

Join Smilow Cancer Hospital on Facebook



Latest Posts:

For Tara Anderson, Physician Assistant in our Hematology Program at the Smilow Cancer Hospital Care Center in North Haven, the COVID-19 pandemic has presented challenges in both her personal and professional life, motivating her to go the extra mile and find work-arounds. Whether implementing new safety protocols for patient safety, or shifting consultations and how patients receive treatment or blood draws, Tara has ensured patients feel safe during this uncertain time. Tara also found a solution for her running group, and they now run touchless relays to stay motivated and active. In fact, word spread about the relays, and there are now 20 women participating in five groups of four. Go Tara!



[Read More >>](#)

Researchers at Yale Cancer Center have reported that treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations. The trial results showed that osimertinib offered a two-year, 89% disease-free survival for patients with resected lung cancer.

Dr. Roy Herbst has followed the development of these drugs since 1997, when the first generation of the drug was developed and tested. "My career is marked by study and use of generations of EGFR inhibitor therapies, and we can

Yanixa Quiñones Avilés, PhD
Candidate, Genetics, Mentor:
Mandar Muzumdar

Basic Science:

Targeted Degradation of Oncogenic
KRASG12C by VHL-recruiting
PROTACs

Michael Bond, PhD

Candidate, Pharmacology, Mentor:
Craig Crews

Clinical Research:

Cost-Effectiveness of First-Line
Ibrutinib versus Third-Line in
Patients with Untreated Chronic
Lymphocytic Leukemia

Kishan Patel, MD Candidate,

Hematology/Oncology, Mentor: Scott
Huntington

Technology Development:

High Spatial Resolution Multiomics
Sequencing of Mouse Embryos via
DBiT-seq

Yang Liu, PhD, Postdoctoral

Associate, Biomedical Engineering,
Mentor: Rong Fan

Translational Research:

Combination of Spatial Protein Data
with Bulk Transcriptional Profiling of
the Same Cohort Shows
Relationships Between RNA and
Protein and Facilitates Combined
Predictive Signatures

Ioannis Vathiotis, MD, Postdoctoral
Associate, Pathology, Mentor: David
Rimm

George Goshua, MD, a fellow in Yale
Cancer Center's Hematology and
Medical Oncology Fellowship
Program, will present a Late
Breaking Oral
entitled *Endotheliopathy is Essential
in COVID-19 Associated*

now show that science and biologic medicine is making a huge impact in the earliest stages of lung cancer," said Herbst, adding: "It's incredible news."



[Read More >>](#)

Today, our #SmilowStars are the nursing team at our Trumbull Care Center for their flexibility and continued commitment to our patients over the last three months during many transitions, changes, and developing protocols. Together, Patti Syx, Denise Paci, Katie Mullins, and Mary McCartney have provided continuous support for a high volume of patients. They have been instrumental in alleviating patient fears and providing relief and comfort during pre-visit screening calls and in-person visits. Their resourcefulness and knowledge has also provided key triage for patient concerns by phone to help eliminate extra visits and provide helpful guidance remotely. Thank you!

Coagulopathy at the **25th Congress of the European Hematology Association (EHA25)** on Sunday, June 14. The work is in collaboration with **Alfred Lee, MD, PhD**, senior author, and other members of the Hematology Program. Their work shares the study of 68 patients hospitalized with COVID-19 at Yale New Haven Hospital, and measurement of endothelial cell and platelet activation markers during a daily blood draw to better understand COVID-19-associated coagulopathy. They found that endotheliopathy and platelet activation are central to the mechanism of COVID-19 coagulopathy and identified soluble thrombomodulin segregation with mortality in an exploratory analysis. The work is a fundamental step forward in understanding the coagulopathy in this disease and given the immediate therapeutic implications has driven changes in the management of patients in our hospital system.

Lajos Pusztai, MD, DPhil, Professor of Medicine (Medical Oncology) has been appointed to serve as a member of **ASCO's Breast Cancer Guideline Advisory Group (GAG)**. The four-year term began on June 3, 2020. GAGs make recommendations to the Clinical Practice Guidelines Committee (CPGC) on identifying and prioritizing topics for guideline development.

Natalia Neparidze, MD, Assistant Professor of Medicine (Hematology) graduated from the **Yale School of Medicine Medical Education Fellowship Program** last week. Her



[Read More >>](#)

Dr. Charles Fuchs, Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital, and Dr. Tara Sanft, Director of the Smilow Cancer Hospital Cancer Survivorship Clinic, welcome you to our Virtual Cancer Survivors' Day Celebration!



[Read More >>](#)

Smilow Cancer Hospital Community Health Educator, Jose DeJesus, and @Sisters' Journey Outreach Coordinator, Lynn Sistruck, exchange supplies to help meet the needs of African American cancer survivors during the current pandemic. Smilow Cancer Hospital and Yale Cancer Center donated masks for their members in need.

final project was titled, "Advancing Hematology Education for Trainees Through Instructional Videos and Self-Assessment Program."




Yuan Huang, PhD, Assistant Professor of Biostatistics, has joined the **Cancer Prevention and Control Research Program**. Her statistical research is highly motivated by modeling large-scale complex datasets including genomic data, which are often featured in complex network structures, low-reproducibility, and high-dimensionality. Dr. Huang's collaborative research interests widely span clinical trials, genetics, epidemiology, and other biomedical fields. She has provided statistical support to multiple clinical trials, including statistical design, conduct



[Read More >>](#)

The preliminary results of a Phase I clinical trial at Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates clinical evidence of anti-tumor responses in patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed prior therapy. The therapy is based on novel research at from Yale by Dr. Craig Crews.

"We are extremely pleased with the current results of this first-in-class, first-in-human Phase I study and anticipate expansion to a Phase II trial once we establish a recommended dose," explained Dr. Daniel Petrylak. "This is a potential new option that approaches treating metastatic castration-resistant prostate cancer in a completely different way."



[Read More >>](#)

Smilow Cancer Hospital believes in maximizing its impact on patient care and cancer science, but also within its local communities. Smilow Cancer Hospital Care Center in Torrington, in collaboration with Agriventures Agway of Litchfield, provided a donation of flower and vegetable seed

and analysis, result interpretation and manuscript preparation.

Alfred Lee, MD, PhD, Associate Professor of Medicine (Hematology) has been appointed to the **American Society of Hematology (ASH) Guideline Panel on Use of Anticoagulation in Patients With COVID-19**. The guidelines will address four distinct populations of people with COVID-19: acutely ill hospitalized patients; critically ill hospitalized patients, e.g., patients in the intensive care unit; patients after hospital discharge; and non-hospitalized patients.

Roy S. Herbst, MD, PhD, Chief of Medical Oncology, has been elected to the **American Association for Cancer Research Board of Directors** for a three-year term in recognition of his outstanding contributions to cancer research and treatment.

Anthony J. Koleske, PhD, a member of Yale Cancer Center's Cancer Signaling Networks Research Program, has been named as the **Ensign Professor of Molecular Biophysics and Biochemistry (MB&B) and of Neuroscience**. Dr. Koleske studies the biochemical mechanisms that control changes in cell shape and movement in order to understand how these processes break down in cancer and brain diseases.


Employee Profile: Laura Snyder, RN

packets to the physicians, nurses, and staff at Charlotte Hungerford Hospital. "This donation is token of our appreciation to our fellow healthcare workers with the hope that the seeds bring some hope of a brighter future," said Debra Brandt, DO, Medical Director, Smilow Cancer Hospital Care Center at Torrington.



[Read More >>](#)


The providers, caregivers, and staff at the Smilow Cancer Hospital Trumbull Care Center have had one less thing to worry about over the last couple of months thanks to the diligent work of Nicole Myer, Ambulatory Care Associate. Nicole has made sure the Care Center has had all the necessary supplies and abundant PPE to safely care for their patients. She also worked hard to help appropriately schedule patients when the Trumbull and Fairfield offices were combined into one location, and is now helping to transition patients back to Fairfield, ensuring adequate coverage throughout the scheduling modifications. Nicole's dedication to our patients and team in Trumbull and Fairfield is commendable, and she is doing all of this while attending school online to complete her nursing degree. Congratulations, Nicole, you're a true #SmilowStar!



As one of two practice nurses supporting the Melanoma and Renal Cell teams, Laura Snyder, RN, enjoys the opportunity to not only help patients, but also work within two areas of cancer specialty comprised of supportive providers who put their patients first.

Laura serves as the point of contact for patients who have questions, but especially for those who are experiencing side effects from treatment or who may be starting immunotherapy. She is there to answer questions and to help talk through their concerns and also fields requests related to financial difficulties, helping coordinate assistance with costs, and connecting patients with a social worker. "Serving as their point person is important to me so patients and their families feel

Smilow Stars



Thank you,
Nicole Myer,
Ambulatory Care
Associate,
at Smilow Cancer
Hospital Trumbull
Care Center!

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

[Read More >>](#)

Take a few minutes to get to know Dr. Anne Chiang, Chief Network Officer for the Smilow Cancer Hospital Care Center Network and a thoracic medical oncologist, a little better in a recent interview.

Get to Know A Caregiver



Anne Chiang, MD, PhD

Associate Professor; Chief Network Officer and
Deputy Chief Medical Officer, Smilow Cancer Network

YaleNewHavenHealth
Smilow Cancer Hospital

Yale CANCER CENTER
A Comprehensive Cancer Center Designated
by the National Cancer Institute

[Read More >>](#)

Follow Yale Cancer Center on
Twitter

Follow us on [twitter](#)

comfortable approaching me with any concerns that may arise throughout their journey," says Laura.

The Melanoma Program recently moved to North Haven, and back to New Haven again, as part of the transition for care of patients with COVID-19. With these moves, Laura helped her patients become familiarized with the new, temporary location, giving them peace of mind during an unsettling time. "The North Haven facility is a beautiful, safe location and it was important to reassure our patients that this transition would be a smooth process," emphasizes Laura. "As part of the process, we have helped patients prepare for Telehealth appointments using the MyChart app."


Laura is appreciative of the many opportunities to learn about the research taking place as well as the new options for treatment. "I work with the best team," she says. "We are constantly busy, but every day it is enjoyable because our team is great!"


Recent Publications


Zeidan, A. M., Wang, R., Wang, X., Shallis, R. M., Podoltsev, N. A., Bewersdorf, J. P., Huntington, S. F., Neparidze, N., Giri, S., Gore, S. D., Davidoff, A. J., & Ma, X.


Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. *Blood advances*, 4(10), 2192-2201.


[Read More >>](#)


 Congratulations to @DrRoyHerbstYale elected to the @AACR Board of Directors for a three-year term for his outstanding contributions to #lungcancer research and treatment.

 Yale Cancer Center scientists led by Dr. Dan DiMaio have developed a new cell screening method to study viral infection and disease, including #COVID19. The findings are out today in @CellReports


 Tune in to .@YaleCancer Answers today at 7:30pm @wnpr to hear Dr. Mandar Muzumdar @MuzumdarLab discuss the latest in #PancreaticCancer research and the role of #genetics and #environmental factors in #cancer.

 Thank you to Dean Nancy Brown, MD . @YaleMed for kicking off our@YaleCancer Trainee Colloquium with a review of her career, mentors, funding, and influences for our trainees and mentees.

 @BillingsleyMD talked to@ctexaminer about the importance of #cancer screenings and safety of appointments during #COVID19.

 New research led by @Halene_Lab @Dr_Yimeng in @ImmunityCP found the absence of m6A alters the structure of #RNA molecules and triggers a detrimental viral immune response, leading to the destruction of blood cells.

 New findings by Dr. Peter Glazer . @Glazerlab in@nresearchnews identified, in a novel way, how abnormal cell metabolism impacts #DNA repair.

 Thank you to Dr. Bishoy Faltas @Faltaslab @WeillCornell for presenting today's @YaleCancer virtual Grand Rounds "Germline-somatic Interactions in the #BladderCancer Genome"

Wernke, K. M., Xue, M., Tirla, A., Kim, C. S., Crawford, J. M., & Herzon, S. B.

Structure and bioactivity of colibactin.

Bioorganic & medicinal chemistry letters, 30(15), 127280.

[Read More >>](#)

Fisher, O. S., Li, X., Liu, W., Zhang, R., & Boggon, T. J.

Crystallographic Studies of the Cerebral Cavernous Malformations Proteins.

Methods in molecular biology (Clifton, N.J.), 2152, 291-302.

[Read More >>](#)

Lu, M., Ma, X., Reichard, N., Terry, D. S., Arthos, J., Smith, A. B., 3rd, Sodroski, J. G., Blanchard, S. C., & Mothes, W.

Shedding-resistant HIV-1 envelope glycoproteins adopt downstream conformations that remain responsive to conformation-preferring ligands.

Journal of virology, JVI.00597-20. Advance online publication.

[Read More >>](#)

Xie, J., Heim, E. N., Crite, M., & DiMaio, D.

TBC1D5-Catalyzed Cycling of Rab7 Is Required for Retromer-Mediated Human Papillomavirus Trafficking during Virus Entry.

Cell reports, 31(10), 107750.

[Read More >>](#)

Angarola, B., & Ferguson, S. M.
Coordination of Rheb lysosomal membrane interactions with mTORC1 activation.



Dr. Alfred Lee discusses what drives #COVID19-associated #coagulopathy in our latest Grand Rounds - watch online



Congratulations to five @YaleCancer @SmilowCancer physicians awarded @ConquerCancerfd research awards during #ASCO20



@DrRoyHerbstYale presents in a poster presentation at #ASCO20 immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in a phase I study.



@ElizabethPrsic will discuss options for end of life patient care and #PalliativeCare on Yale Cancer Answers today at 7:30pm @wnpr. Listen live or download our podcast through @iTunes



In a poster presentation at #ASCO20, Dr. Rozalyn Rodwin reports on neuropathy in survivors of childhood central nervous system tumors in the @StJude Lifetime cohort.



In a poster presentation at #ASCO20, @MarioSznol presents results of #Immunotherapy Phase II trial of Voyager-VI in combination with cemiplimab in patients with #NSCLC, #melanoma, HCC or endometrial carcinoma.



At #ASCO20 in a poster presentation, @TaraSanftMD reports findings for delivery of #cancersurvivorship education to community health care professionals.



Watching virtual #ASCO20 today? At 4pm, @DanPetrylak will present data showing clinical evidence of anti-tumor activity in patients with advanced #prostatecancer.



@RanjanPathk presents poster results with Dr. Sarah Goldberg from study showing comparative efficacy of chemoimmunotherapy versus #immunotherapy alone in the front-line treatment of advanced #NCSLC.

F1000Research, 9, F1000 Faculty Rev-450.

[Read More >>](#)

Xiao, C., Eldridge, R. C., Beitler, J. J., Higgins, K. A., Chico, C. E., Felger, J. C., Wommack, E. C., Knobf, T., Saba, N. F., Shin, D. M., Bruner, D. W., & Miller, A. H.

Association Among Glucocorticoid Receptor Sensitivity, Fatigue, and Inflammation in Patients With Head and Neck Cancer.

Psychosomatic medicine, 82(5), 508-516.

[Read More >>](#)

Giri, S., Aryal, M. R., Yu, H., Grimshaw, A., Pathak, R., Huntington, S. P., & Dhakal, B.

Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis.

Journal of geriatric oncology, S1879-4068(20)30064-3. Advance online publication.

[Read More >>](#)

Leapman, M. S., Presley, C. J., Zhu, W., Soulos, P. R., Adelson, K. B., Miksad, R. A., Boffa, D. J., & Gross, C. P.

Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.

JAMA network open, 3(6), e207205.

[Read More >>](#)



57-year old Jenn is doing well after participating in ADAURA trial@SmilowCancer Hospital @SaintFrancisCT. Results reported at #ASCO20 show osimertinib significantly increases disease free survival in patients like Jenn w/early stage #NSCLC.



Dr. Joseph Kim presents poster results at #ASCO20 with Dr. Patricia LoRusso showing preliminary efficacy data of platinum-pretreated #SCLC cohort of NCI 9881 study.



Don't miss .@DrRoyHerbstYale presenting research results from ADAURA trial during the plenary session at 1pm today at virtual #ASCO20. Osimertinib offered a two-year, 89% DFS for patients with certain #NSCLC.



Coming up at 11am at virtual #ASCO20, . @CharlesFuchsMD presents updated research results in an oral abstract from KEYNOTE-061 trial showing a correlation to PD-L1 expression for #gastriccancer patients.



@BarbaraBurtness will be a Discussant at virtual #ASCO20 for the 11am Oral Abstract Session titled "Hitting the Bullseye: Evolving Role of Targeted and Immune Therapy in #GastroesophagealCancers."



In a poster presentation at #ASCO20, Dr. Patricia LoRusso led research w/Dr. Kurt Schalper on a phase 2 study of PARP inhibition w/anti-PD-L1 therapy in homologous #DNA repair deficient, locally advanced or metastatic non HER2+ #breastcancer.



@NavidHafez led research with Dr. Joseph Kim in a poster presentation at #ASCO20 showing preliminary efficacy data from a phase II study of triple-negative #breastcancer cohort of NCI 9881 study.



In a poster presentation at #ASCO20, . @JuliaFoldiMD led research w/ @tarasanftmd showing Local/Regional/Adjuvant Adherence to extended adjuvant endocrine therapy following #BreastCancer Index testing in women w/ early HR+ breast cancers.

Politi K.

Leveraging Patient-Derived Models for Immunotherapy Research.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 40, e344-e350.

[Read More >>](#)

Schulman-Green, D., Cherlin, E., Capasso, R., Mougalian, S. S., Wang, S., Gross, C. P., Bajaj, P. S., Eakle, K., Patel, S., Douglas, K., & Adelson, K.

Patient and Family Caregiver Considerations When Selecting Early Breast Cancer Treatment: Implications for Clinical Pathway Development.

The patient, 10.1007/s40271-020-00426-7. Advance online publication.

[Read More >>](#)

Khadraoui, W., Tierney, C., Chung, S., Mutlu, L., Lu, L., Azodi, M., Ratner, E., & Menderes, G.

Risk-stratifying clinicopathologic criteria for ovarian preservation in premenopausal women with early stage low-risk endometrial cancer.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 10.1002/ijgo.13254. Advance online publication.

[Read More >>](#)

Grossman, S. A., Romo, C. G., Rudek, M. A., Supko, J., Fisher, J., Nabors, L. B., Wen, P. Y., Peereboom, D. M., Ellingson, B. M.,



Dr. Alessandro Santin gives results from a phase I/II clinical trial of Sacituzumab govitecan in patients with previously treated metastatic #endometrialcancer in a poster presentation at #ASCO20.



In a poster presentation at virtual #ASCO20, @encheng23 reported on long-term #cancer survival in cohorts of U.S. health professionals.



In a poster presentation led by @CPresGeriOncMD with @cpgYALE at #ASCO20, findings on aggressive care at end-of-life in the Veteran's Health Administration versus fee-for-service Medicare among patients w/advanced #lungcancer.



At #ASCO20 in a poster presentation led by . @VikramJairamMD with @HenryParkMD , findings on symptoms and survivorship temporal trends in opioid prescribing patterns among oncologists in the Medicare population.



@BarbaraBurtness reported in a poster presentation at #ASCO20 on #headandneckcancer correlation of tumor mutational burden with CDKN2A and TP53 mutation in #HPV-negative head and neck squamous cell carcinoma.



In a poster presentation at virtual #ASCO20 today, . @Dr_AmerZeidan reported results of treatment with Glasdegib in combination with azacitidine in patients with untreated higher-risk #MDS#AML & #CMML.



@FauziaRiaz with @cpgYALE reported in a poster presentation at #ASCO20 on the adoption of immune #checkpointinhibitors and patterns of care at the end of life.

Calendar

Phone Meditation hosted by Smilow Integrative Medicine

June 12; 1:00 PM

[Learn More >>](#)

Yale Cancer Answers

June 14; 7:30 PM

NPR

Elmquist, W., Barker, F. G., Kamson, D., Sarkaria, J. N., Timmer, W., Bindra, R. S., Ye, X., & Adult Brain Tumor Consortium
Baseline Requirements for Novel Agents Being Considered for Phase II/III Brain Cancer Efficacy Trials: Conclusions from the Adult Brain Tumor Consortium's First Workshop on CNS Drug Delivery.

Neuro-oncology, noaa142. Advance online publication.

[Read More >>](#)

Cheng, E., Hung, P., & Wang, S. Y.

Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study.

Journal of the National Comprehensive Cancer Network : JNCCN, 18(6), 729-736.

[Read More >>](#)

Vejnar, C. E., & Giraldez, A. J.
LabxDB: Versatile databases for genomic sequencing and lab management.

Bioinformatics (Oxford, England), btaa557. Advance online publication.

[Read More >>](#)

Fabris, L., Sato, K., Alpini, G., & Strazzabosco, M.

The Tumor Microenvironment in Cholangiocarcinoma Progression.

Hepatology (Baltimore, Md.), 10.1002/hep.31410. Advance online publication.

[Read More >>](#)

Breast Cancer Surgery

Tristen Park, MD

[Learn More >>](#)

Guided Imagery Meditation with Michele Grand LMT hosted by Smilow Integrative Medicine

June 15; 10:30 AM

[Learn More >>](#)

Virtual T'ai Chi/Qigong hosted by Smilow Integrative Medicine

June 15; 3:00 PM

[Learn More >>](#)

Schwartz Center Rounds

June 16; 12:00 PM

Embracing Diversity and Inclusion

Jennifer Kapo, MD | Tara Sanft, MD | Darin Latimore, MD | Katherine Tucker, DNP, RN, APRN-BC, NE-BC | Charles Fuchs, MD | Lori Pickens | Kevin Billingsley, MD, MBA, FACS | Kim Slusser, RN | Ena Williams

[Learn More >>](#)

Phone Meditation hosted by Smilow Integrative Medicine

June 16; 12:30 PM

[Learn More >>](#)

Zumba Gold hosted by Smilow Integrative Medicine

June 16; 1:00 PM

[Learn More >>](#)

Restorative Yoga with Ellen McNally hosted by Smilow Integrative Medicine

June 16; 3:00 PM

[Learn More >>](#)

Virtual T'ai Chi/Qigong hosted by Smilow Integrative Medicine

June 17; 2:00 PM

[Learn More >>](#)

Phone Meditation hosted by Phil Levine, Mindfulness Meditation Coach

June 17; 6:00 PM

[Learn More >>](#)

2020 Yale Urology Bernard Lytton Visiting Professorship Virtual Conference

June 18; 8:00 AM

Peter Schulam, MD, PhD | Michael Leapman, MD | Preston Sprenkle, MD | Sam Chang, MD, MBA | Juan Javier-DesLoges, MD | Cayce Nawaf, MD | Jeannie Su, MD | Richard Ho, MD | Marianne Casilla-Lennon, MD | Jamil Syed, MD | Alexander Bandin, MD | Jay Amin, MD | Katelyn Johnson, MD | Justin Nguyen, MD | Daniel Segal, MD

[Learn More >>](#)

Virtual Gentle Yoga hosted by Smilow Integrative Medicine

Hong, C. S., & Moliterno, J.
**The Patient-Centered Approach:
A Review of the Literature and Its
Application for Acoustic
Neuromas.**

Journal of neurological surgery.
Part B, Skull base, 81(3), 280-286.
[Read More >>](#)

Cheng, E., Zhang, S., Ou, F. S.,
Mullen, B., Ng, K., Saltz, L. B.,
Niedzwieck, D., Mayer, R. J.,
Mowat, R. B., Whittom, R., Hantel,
A., Benson, A., Atienza, D.,
Messino, M., Kindler, H.,
Giovannucci, E. L., Van Blarigan, E.
L., Meyerhardt, J. A., & Fuchs, C.
S.

**The Diet of Higher Insulinemic
Potential Is Not Associated with
Worse Survival in Patients with
Stage III Colon Cancer (Alliance).**

Cancer epidemiology, biomarkers &
prevention : a publication of the
American Association for Cancer
Research, cosponsored by the
American Society of Preventive
Oncology, cebp.1454.2019.
Advance online publication.
[Read More >>](#)

Gao, Y., Vasic, R., Song, Y., Teng,
R., Liu, C., Gbyli, R., Biancon, G.,
Nelakanti, R., Lobben, K., Kudo, E.,
Liu, W., Ardasheva, A., Fu, X.,
Wang, X., Joshi, P., Lee, V., Dura,
B., Viero, G., Iwasaki, A., Fan, R.,
... Halene, S.

**m6A Modification Prevents
Formation of Endogenous
Double-Stranded RNAs and
Deleterious Innate Immune
Responses during Hematopoietic
Development.**

Immunity, S1074-7613(20)30184-9.
Advance online publication.

June 18; 10:00 AM

[Learn More >>](#)

**Guided Imagery and Massage with Michele Grand LMT
hosted by Smilow Integrative Medicine**

June 18; 1:30 PM

[Learn More >>](#)

Cancer Genetics and Prevention Program Seminar

June 18; 2:30 PM

[Learn More >>](#)

Phone Meditation hosted by Smilow Integrative Medicine

June 19; 1:00 PM

[Learn More >>](#)

Yale Cancer Answers

June 21; 7:30 PM

NPR

Cognitive Decline after Prostate Cancer

Herta Chao, MD, PhD

[Learn More >>](#)

**Guided Imagery Meditation with Michele Grand LMT
hosted by Smilow Integrative Medicine**

June 22; 10:30 AM

[Learn More >>](#)

**Virtual T'ai Chi/Qigong hosted by Smilow Integrative
Medicine**

June 22; 3:00 PM

[Learn More >>](#)

Yale Cancer Center Grand Rounds

June 23; 12:00 PM

Chen Liu, MD, PhD

[Learn More >>](#)

Phone Meditation hosted by Smilow Integrative Medicine

June 23; 12:30 PM

[Learn More >>](#)

Zumba Gold hosted by Smilow Integrative Medicine

June 23; 1:00 PM

[Learn More >>](#)

**Restorative Yoga with Ellen McNally hosted by Smilow
Integrative Medicine**

June 23; 3:00 PM

[Learn More >>](#)

**Virtual T'ai Chi/Qigong hosted by Smilow Integrative
Medicine**

June 24; 2:00 PM

[Learn More >>](#)

**Phone Meditation hosted by Phil Levine, Mindfulness
Meditation Coach**

June 24; 6:00 PM

[Read More >>](#)

Funding Opportunities

DoD FY20 Melanoma Research Program

MRP is invested in research focusing on the prevention, detection, diagnosis, and treatment of melanoma for the benefit of Service members, Veterans, their families, and the American public.

Idea Award - Letter of Intent

Due: June 22, 2020

Mid-Career Accelerator - Letter of Intent Due: June 22, 2020

Team Science Award - Letter of Intent Due: June 22, 2020

Technology Development

Partnership Award - Letter of Intent Due: June 22, 2020

Translational Research

Award - Letter of Intent Due: June 22, 2020

Translational Research

Award Collaborator

Option - Letter of Intent Due: June 22, 2020

[Learn More >>](#)

Urgent Competitive Revision and Administrative Supplements on COVID-19

The NCI is issuing this Notice of Special Interest to highlight the urgent need for research on COVID-19 and the effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), on cancer, and vice versa.

Application Deadline: June 26, 2020

[Learn More >>](#)

[Learn More >>](#)

Submissions

Please submit your recent publication and grant announcements to:

Renee Gaudette

Director, Public Affairs and Communications

Competitive Revision SBIR/STTR Supplements on COVID-19

The SBIR/STTR programs at the NCI are issuing this Notice of Special Interest to highlight the urgent need for the development of prophylactic, therapeutic and diagnostic for Coronavirus Disease 2019 (COVID-19).

Application Deadline: June 26, 2020

[Learn More >>](#)

AACR-Bayer Stimulating Therapeutic Advances through Research Training (START) Grants

These grants provide support to postdoctoral or clinical research fellows and combine research experiences in both an academic and industry setting, following a research timeline that will be of greatest benefit to the proposed work.

Application Deadline: June 30, 2020

[Learn More >>](#)

Damon Runyon-Rachleff Innovation Award

This award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer.

Application Deadline: July 1, 2020

[Learn More >>](#)

The Hope Foundation for Cancer Research: SWOG/Hope Foundation Impact Award

The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects.

Application Deadline: July 1, 2020

[Learn More >>](#)

FY20 Ovarian Cancer Research Program Proteogenomics Research Award

This Research Award supports the use of proteomics and/or genomics to explore new concepts or theories in ovarian cancer. The award is intended to support the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.

Letter of Intent Due: July 16, 2020

[Learn More >>](#)

DeLuca Pilot Award Grants

Five pilot awards will be awarded to support investigators participating in Hematology research for the purpose of establishing research collaborations between scientists/researchers at Yale and primary Hematology faculty and to generate preliminary data and evidence of collaboration for new NCI/NIH grant applications. The research should seek to advance our knowledge in hematologic disorders and to improve patient care, therapies, and outcomes.

Application Deadline: July 20, 2020

[Learn More >>](#)

Serological Sciences Network (SeroNet) RFAs

- Research Projects in SARS-CoV-2 Serological Sciences (U01)
- SARS-CoV-2 Serological Sciences Centers of Excellence (U54)

Funding for these RFAs was provided through Congressional appropriation enacted in response to the COVID-19 pandemic to NCI "to develop, validate, improve, and implement serological testing and associated technologies." In response, NCI intends to use this emergency appropriation in part to establish a Serological Sciences Network to which these RFAs correspond.

Application Deadlines: July 22, 2020

[Learn More >>](#)

Breast Cancer Alliance Young Investigator Grant

To encourage a commitment to breast cancer research, Breast Cancer Alliance invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers, to apply for funding for the Young Investigator Grant.

Application Deadline: July 24, 2020

[Learn More >>](#)

Strengthening Institutional Capacity to Conduct Global Cancer Research in Low- and Middle-Income Countries (D43)

The purpose of this FOA is to establish an institutional program for mentored training in global cancer research.

Application Deadline: July 24, 2020

[Learn More >>](#)

2020 Yale Cancer Center Internal Pilot Grant Competition

These grants will support all potential areas of innovative cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research.

Application Deadline: August 1, 2020

[Learn More >>](#)

DoD FY20 Kidney Cancer Research Program

The KCRP focuses on the issues regarding prevention, detection, treatment, and the long-term effects of treatment for kidney cancer for Service Members, Veterans, their families, and the American public.

Early Career Investigator

Award - Letter of Intent Due: August 5, 2020

Concept Award - Letter of Intent Due: July 15, 2020

Translational Research

Partnership Award - Letter of Intent Due: August 5, 2020

[Learn More >>](#)

NIH Support for Conferences and Scientific Meetings (Parent R13)

The purpose of the NIH Research Conference Grant (R13) is to support high quality scientific conferences that are relevant to the

NIH's mission and to the public health.

Application Deadline: August 12, 2020

[Learn More >>](#)

NCCN Pfizer Axitinib Request for Proposals (RFP)

NCCN and Pfizer are collaborating to offer a new grant opportunity seeking proposals to support NCCN Member Institution faculty utilizing axitinib. The overall aim is to develop innovative trials that will evaluate the role of axitinib in the treatment of melanoma, hepatocellular carcinoma, and colorectal cancer.

Application Deadline: August 12, 2020

[Learn More >>](#)

Lasker Clinical Research Scholars Program (Si2/R00)

This FOA encourages applications for the Lasker Clinical Research Scholars Program for the purpose of supporting the research activities during the early stage careers of independent clinical researchers.

Application Deadline: August 28, 2020

[Learn More >>](#)